Dr. Weiquan Li, Senior Director of Research and Development, graduated from Shanghai Institute of Plant Ecology and Physiology, Chinese Academy of Sciences, and completed postdoctoral research in the Medical School of the University of Michigan, USA. He has more than 20 years of basic research and drug research and development experience in the fields of cancer and aging, and once worked as a part-time professor and doctoral supervisor in Central South University. He has held important positions in many companies and presided over the company's research and development work. He has presided over or participated in more than 10 research projects in China and the United States (including the National Natural Science Foundation of China research projects and research projects funded by the United States Department of Defense), achieved a series of important research results, won many awards at home and abroad, and published about 30 high-quality academic papers in SCI academic journals. The impact factor value (IF) was over 20 in 3 papers and over 10 in 15 papers. The cumulative impact factor value (IF) exceeds 300 points, and the paper has been cited more than 2500 times. He has submitted more than 20 patent applications as the main inventor. In 2023, I will work for Encore Immunity and lead the research and development of the company's drug Discovery Department, studying the molecular mechanism of drug action and carrying out the research on the internal and external clinical efficacy of related drugs.